ArticlePloS one2024
An explainable ensemble approach for advanced brain tumor classification applying Dual-GAN mechanism and feature extraction techniques over highly imbalanced data.
Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An Efficient and Cohesive System for Enhanced Accuracy in Malignant Brain Tumor Diagnosis.Current medical imaging · 2026Article
- A novel hybrid framework integrating GA-driven 3D ResUNetGAN for MRI brain tumor segmentation.PloS one · 2026Article
- A Hybrid Ensemble Learning Framework for Predicting Lumbar Disc Herniation Recurrence: Integrating Supervised Models, Anomaly Detection, and Threshold Optimization.Diagnostics (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumors are one of the leading diseases imposing a huge morbidity rate across the world every year. Classifying brain tumors accurately plays a crucial role in clinical diagnosis and improves the overall healthcare process. ML techniques have shown promise in accurately classifying brain tumors based on medical imaging data such as MRI scans. These techniques aid in detecting and planning treatment early, improving patient outcomes. However, medical image datasets are frequently affected by a significant class imbalance, especially when benign tumors outnumber malignant tumors in number. This study presents an explainable ensemble-based pipeline for brain tumor classification that integrates a Dual-GAN mechanism with feature extraction techniques, specifically designed for highly imbalanced data. This Dual-GAN mechanism facilitates the generation of synthetic minority class samples, addressing the class imbalance issue without compromising the original quality of the data. Additionally, the integration of different feature extraction methods facilitates capturing precise and informative features. This study proposes a novel deep ensemble feature extraction (DeepEFE) framework that surpasses other benchmark ML and deep learning models with an accuracy of 98.15%. This study focuses on achieving high classification accuracy while prioritizing stable performance. By incorporating Grad-CAM, it enhances the transparency and interpretability of the overall classification process. This research identifies the most relevant and contributing parts of the input images toward accurate outcomes enhancing the reliability of the proposed pipeline. The significantly improved Precision, Sensitivity and F1-Score demonstrate the effectiveness of the proposed mechanism in handling class imbalance and improving the overall accuracy. Furthermore, the integration of explainability enhances the transparency of the classification process to establish a reliable model for brain tumor classification, encouraging their adoption in clinical practice promoting trust in decision-making processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.